Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

ngs derived from Anadys' completed strategic restructuring.

Operating expenses were $9.7 million for the third quarter of 2008, compared to $10.0 million for the third quarter of 2007. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million and $1.4 million for the third quarter of 2008 and 2007, respectively.

The net loss was $9.3 million for the third quarter of 2008, compared to net income of $12.3 million for the third quarter of 2007. Basic and diluted net loss per common share was $0.32 in the third quarter of 2008, compared to net income per common share of $0.43 in the third quarter of 2007. Non-cash share-based expense resulted in a $0.03 increase in basic and diluted net loss per share for the third quarter of 2008 compared to a $0.05 decrease in basic and diluted net income per share for the third quarter 2007.

During the nine months ended September 30, 2008 the Company had no revenue, compared to $23.9 million for the same period in 2007. The revenue recognized in the first nine months of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration and the recognition of the previously deferred revenue upon termination of the collaboration. Operating expenses during the nine months ended September 30, 2008 were $25.2 million compared to $28.1 million for the nine months ended September 30, 2007. The decrease in operating expenses was a result of cost savings derived from Anadys' completed restructuring partially offset by increases in development costs for ANA598 and ANA773. For the nine months ended September 30, 2008, Anadys reported a net loss of $23.9 million, compared to $1.4 million for the same period last year. Basic and diluted net loss per common share was $0.83 for the nine months ended September 30, 2008, compared to $0.05 for the same period in 2007.

Recent Development Program Highlights

-- Phase
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Bill Jacobs Automotive, a group of car ... up with the Heartland Blood Center and offering free oil ... drive takes place Saturday, Jan. 18 at the Bill Jacobs ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... China, notified,its shareholders today that the Annual ... 2007, has been postponed due the geographical,nature ... the mailing of,proxy materials. The Company is ...
... EDMONTON, Aug. 20 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), announced,today that it is ... bid,which will be conducted pursuant to the rules ... purchase up to 1,000,000 of its Class A ...
... ABUJA, August 20 The Chrome Group today announced ... of its companies on trading,platforms in Europe and the ... Group Chief Communications Officer, Mr. Val Oji said that ... Group was,implementing over the next two years. Chrome recently ...
Cached Biology Technology:Sinovac Announces Postponement of Annual General Meeting 2BioMS Medical announces its intention to renew a normal course issuer bid 2Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4
(Date:4/21/2014)... can help treat and prevent influenza and respiratory ... the lungs and breathing passages, according to research ... new Institute for Biomedical Sciences. , In a ... upcoming publication of the International Journal of Molecular ... ginseng, a well-known herbal medicine, on human health. ...
(Date:4/21/2014)... Like a daily pill to lower cholesterol can reduce ... reduces eye inflammation could help save the vision of ... already targeted with high doses of niacin to decrease ... also be an effective mark for these patients, said ... Georgia at Georgia Regents University. , Martin is ...
(Date:4/21/2014)... domesticated chili pepper now the world,s most ... team of researchers, led by a plant scientist ... from the four-pronged investigation based on linguistic ... traditional archaeological and genetic data suggest a ... the domesticated chili pepper. That region, extending from ...
Breaking Biology News(10 mins):Ginseng can treat and prevent influenza and RSV, researcher finds 2Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Birthplace of the domesticated chili pepper identified in Mexico 2
... Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link ... blood. In the long term, the research may well help ... been published in the Journal of the American College ... which the opening of the aortic valve is narrowed ...
... PULLMAN, Wash. A class of drugs used to treat ... treating cancers and immune-related diseases, a new WSU-led study has ... have a major impact on its ability to affect specific ... "This was rather unexpected, given how relatively simple the molecules ...
... iPhone users now have access to a free ... including electricity, natural gas, biodiesel, e85 Ethanol, propane ... Energy Laboratory (NREL) developed the new mobile application ... local stakeholders across the country in an effort ...
Cached Biology News:Danish researchers predict risk of valvular heart disease 2Researcher finds potential new use for old drugs 2NREL developed mobile app for alternative fueling station locations released 2
... Immunogen: Synthetic peptide derived from the C ... protein This peptide sequence is downstream ... Zymed polyclonal Connexin 36 antibody Cat. No. ... 36. Reactivity: Mouse (positive control: mouse ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: